MICHAEL E MENDELSOHN, M.D.
Osteopathic Medicine at Washington St, Boston, MA
License number
Massachusetts 52533
Category
Osteopathic Medicine
Type
Internal Medicine
Address
Address
2
750 Washington St, Boston, MA 02111
14 Emerson Rd, Wellesley, MA 02481
14 Emerson Rd, Wellesley, MA 02481
Phone
(617) 636-9370
Personal information
See more information about MICHAEL E MENDELSOHN at radaris.comName
Address
Phone
378 Walnut St, Newtonville, MA 02460
59 School St, Woods Hole, MA 02543
59 Sumner Rd, Brookline, MA 02445
154 Cherry St, Framingham, MA 01701
276 Corey Rd APT 44, Brighton, MA 02135
Professional information
Dr. Michael E Mendelsohn, Boston MA - MD (Doctor of Medicine)
Specialties:
Cardiology
Address:
220 Boylston St SUITE 1103, Boston 02116
TUFTS NEW ENGLAND MEDICAL CENTER
750 Washington St, Boston 02111
(617) 636-5846 (Phone), (617) 636-5913 (Fax)
TUFTS NEW ENGLAND MEDICAL CENTER
750 Washington St, Boston 02111
(617) 636-5846 (Phone), (617) 636-5913 (Fax)
Certifications:
Cardiovascular Disease, 1987, Internal Medicine, 1985
Awards:
Healthgrades Honor Roll
Languages:
English, French
Education:
Medical School
Harvard Med Sch
Graduated: 1982
Brigham and Womens Hospital
Harvard Med Sch
Graduated: 1982
Brigham and Womens Hospital
Michael E Mendelsohn, Boston MA
Specialties:
Internist
Address:
750 Washington St, Boston, MA 02111
Education:
Harvard Medical School - Doctor of Medicine
Brigham & Women's Hospital - Fellowship - Cardiology
Brigham & Women's Hospital - Fellowship - Cardiology
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Sub-certificate in Cardiovascular Disease (Internal Medicine)
Michael Edward Mendelsohn, Boston MA
Specialties:
Internal Medicine, Cardiovascular Disease, Cardiology
Work:
Tufts Medical Center
750 Washington St, Boston, MA 02111
750 Washington St, Boston, MA 02111
Education:
Harvard University(1982)
Methods For Identifying Vasoprotective Agents
US Patent:
6448019, Sep 10, 2002
Filed:
Oct 1, 1999
Appl. No.:
09/410820
Inventors:
Michael E. Mendelsohn - Wellesley MA
Richard H. Karas - Franklin MA
Richard H. Karas - Franklin MA
Assignee:
New England Medical Center Hospitals, Inc. - Boston MA
International Classification:
G01N 3353
US Classification:
435 71, 435 772, 435 78, 435 6, 435 691, 435 911, 435 912, 435325, 435375, 435244
Abstract:
The invention features screening methods which can be used to identify agents, known as vasoprotective agents, which inhibit vascular smooth muscle cell activation and/or proliferation or enhance vascular endothelial cell activation and/or proliferation or activate estrogen responsive genes in vascular cells. Preferred vasoprotective agents are relatively vasospecific, i. e. , their effect on one or more types of vascular cells is more pronounced than their effect on other cell types. Treatment with such vasospecific agents will generally be associated with fewer undesirable side-effects than treatment with estrogen. The methods of the invention are screening assays in which candidate agents are examined to identify vasoprotective agents. One type of screening assay involves examining the effect of a candidate agent on cell proliferation and/or cell activation. Another type of screening assay involves examining the effect of a candidate agent on the expression of a gene which is responsive to estrogen.
Methods For Identifying Cardiovascular Agents
US Patent:
6692928, Feb 17, 2004
Filed:
Oct 12, 1999
Appl. No.:
09/415623
Inventors:
Michael E. Mendelsohn - Wellesley MA
Richard H. Karas - Franklin MA
Richard H. Karas - Franklin MA
Assignee:
New England Medical Center Hospitals, Inc. - Boston MA
International Classification:
G01N 3353
US Classification:
435 78, 4353201
Abstract:
The invention features assays to identify cardiovascular agents, such as vasoprotective agents, antihypertensive agents, cardiomyopathy therapeutic agents, coronary heart disease therapeutic agents, or heart failure therapeutic agents. The assays include culturing cells in the presence or absence of a predetermined amount of the candidate agent and measuring the expression or activity of selected genes or reporter constructs known to be responsive to estrogen.
Methods For Discovery Of Vasoactive Compounds For The Nitric Oxide-Cyclic Gmp Signal Pathway
US Patent:
6352833, Mar 5, 2002
Filed:
Apr 28, 1999
Appl. No.:
09/301099
Inventors:
Michael E. Mendelsohn - Wellesley MA 02181
International Classification:
G01N 33566
US Classification:
435 72, 435183, 435194, 435325, 530350
Abstract:
The invention features methods for assaying compounds that affect the activation of a cell. The methods include measurement of cell activation, G protein-coupled receptor phosphorylation, or phosphorylation of proteins associated with the G-protein-coupled receptor, in a system comprising G protein-coupled receptor-bearing cells, or preparations thereof, cyclic GMP, or analogs thereof, and cyclic GMP-dependent protein kinase.
Compositions Involving M-Rip, And Related Methods For Screening For Anti-Hypertensive Agents, And Uses Thereof
US Patent:
7122655, Oct 17, 2006
Filed:
Nov 17, 2003
Appl. No.:
10/715632
Inventors:
Michael E. Mendelsohn - Wellesley MA, US
Howard K. Surks - Newton MA, US
Howard K. Surks - Newton MA, US
Assignee:
New England Medical Center Hospital, Inc. - Boston MA
International Classification:
A61K 38/16, C07H 21/04, C12N 9/16
US Classification:
536 235, 435 19, 435 691, 435 6, 4353201, 435325, 435196, 514 7, 514929, 514930, 536 232
Abstract:
The present invention relates to screening methods that make use of Myosin Phosphatase-Rho interacting Protein (M-RIP) for the identification of novel therapeutics for hypertension and hypertensive conditions. Also disclosed are methods for treating or preventing hypertension or hypertensive conditions by administering to a mammal a therapeutically effective amount of an agent that reduces the level or activity of M-RIP. According to this invention, the agent decreases contractile and increases relaxant effects of smooth muscle cells, ultimately decreasing the systemic blood pressure of a mammal. For example, the agent may reduce binding of M-RIP to myosin phosphatase, RhoA, or both.
Method For Assaying Compounds Affecting Cell Division Using Estrogen Receptor Beta (Erβ) And Mitosis Arrest Deficient 2 (Mad2)
US Patent:
6867008, Mar 15, 2005
Filed:
Jul 13, 1999
Appl. No.:
09/352570
Inventors:
Michael E. Mendelsohn - Wellesley MA, US
Assignee:
New England Medical Center Hospitals, Inc. - Boston MA
International Classification:
G01N033/53
US Classification:
435 72, 435 71, 435 78, 435 76
Abstract:
The invention provides a method for assaying compounds that affect cell division by determining the interaction between estrogen receptor ERβ and MAD2, a cell cycle checkpoint protein.
Methods For Identifying The Presence Of A Bicuspid Aortic Valve
US Patent:
2013004, Feb 14, 2013
Filed:
Aug 20, 2010
Appl. No.:
13/520095
Inventors:
Gordon Huggins - Bedford MA, US
Eric Wooten - Boston MA, US
Michael Mendelsohn - Boston MA, US
Eric Wooten - Boston MA, US
Michael Mendelsohn - Boston MA, US
Assignee:
Tufts Medical Center ,Inc. - Boston MA
International Classification:
C40B 30/04, C07H 21/04, C40B 40/06, C12Q 1/68
US Classification:
506 9, 435 611, 536 2431, 536 2433, 506 16
Abstract:
The present invention features a method for identifying a subject with a bicuspid aortic valve (BAV) by detecting one or more single nucleotide polymorphisms (SNPs) present in one or more BAV-associated chromosomal regions (e.g., chromosomal regions containing the AXIN1-PDIA2, ENG, BAT2/3, or ZNF385D gene(s)).
Methods For Diagnosing Blood Vessel Reocclusion
US Patent:
2010032, Dec 23, 2010
Filed:
Jun 9, 2010
Appl. No.:
12/797144
Inventors:
Navin K. Kapur - Hanover MA, US
Richard H. Karas - Franklin MA, US
Michael Mendelsohn - Boston MA, US
Richard H. Karas - Franklin MA, US
Michael Mendelsohn - Boston MA, US
Assignee:
Tufts Medical Center, Inc. - Boston MA
International Classification:
C12Q 1/48
US Classification:
435 15
Abstract:
The present invention features a method of diagnosing blood vessel reocclusion in a subject by detecting increased levels of sFLT-1 in a biological sample from the subject.